Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Total Non-Current Liabilities (2016 - 2025)

United Therapeutics' Total Non-Current Liabilities history spans 17 years, with the latest figure at $560.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 24.05% year-over-year to $560.6 million; the TTM value through Dec 2025 reached $560.6 million, down 24.05%, while the annual FY2025 figure was $560.6 million, 24.05% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $560.6 million at United Therapeutics, up from $546.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q3 2023 and bottomed at $527.1 million in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $1.1 billion (2021), against an average of $976.3 million.
  • The largest annual shift saw Total Non-Current Liabilities rose 11.49% in 2023 before it crashed 43.46% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.1 billion in 2021, then increased by 3.42% to $1.1 billion in 2022, then decreased by 3.39% to $1.1 billion in 2023, then crashed by 33.17% to $738.1 million in 2024, then dropped by 24.05% to $560.6 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Total Non-Current Liabilities are $560.6 million (Q4 2025), $546.3 million (Q3 2025), and $527.1 million (Q2 2025).